1 FattovichG.Natural history and prognosis of hepatitis B. Semin Liver Dis, 2003,23:47-58.
2 Vergara M, Gallach M,Dalmau B, et al.Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience. Gastroenterol Hepatol, 2008, 31: 274-279.
3 Kim V,Abreu RM,Nakagawa DM,et al. Pegylated interferon alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat, 2015, May 13, doi: 10.1111/jvh.12418[Epub ahead of print].
4 van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.Liver Int, 2006,26: 399-405.
5 ter Borg F, ten Kate FJ, Cuypers HT, et al. A survey of liver pathology in needle biopsies from HBsAg and anti-HBe positive individuals. J Clin Pathol, 2005,53:541-548.
6 Park JY, Park YN, Kim DY, et al.High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels.J Viral Hepat, 2008,15:615-621.
7 纪永健,李菲菲,任万华,等. HBeAg早期下降对聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的疗效预测. 中华肝脏病杂志,2013,21:335-339.
8 Kumar M, Sarin SK, Hissar S, et al.Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology, 2008,134:1376-1384.
9 Wu IC,Lai CL,Han SH, et al.Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology, 2010, 51:1185-1189.
10 Hansen BE, Buster EH,Steyerberg EW, et al.Prediction of the response to peg-Interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol, 2010,82:1135-1142.
11 Mommeja-Marin H, Mondou E, Blum MR, et al.Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology, 2003,37:1309-1319.
12 Jang JW, Choi JY, Bae SH, et al.The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer, 2007,110:1760-1767.
13 Di Bisceglie AM.Hepatitis B and Hepatocellular Carcinoma. Hepatology, 2009,49(5 Suppl): S56-S60.
14 Yeo W, Mo FK, Chan SL, et al.Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology, 2007,45:1382-1389.
15 Huang Y, Wang Z, An S, et al.Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol, 2008,80:591-597. |
